Navigation

Investiment.io
Financial analysis platform

Altria Group, Inc.

MO β€’ NYSE

$78.90
β–²0.26 (0.33%)β€’ REGULAR

Altria Group, Inc.

$78.90
β–²0.3%
πŸ“ŠSummaryπŸ“‹SEC FilingsπŸ‘₯Insider Trading
πŸ“„

MO Q3 2024 Earnings Call

October 31, 2024 at 12:00 AM

Company
MO
Quarter
Q3 2024
Date
October 31, 2024 at 12:00 AM
Speakers
2
Word Count
~5,739

Transcript Content

Operator
Thank you. Our first question comes from Matt Smith with Stifel. Please go ahead.
Speaker
Hey, good morning. Billy Gifford (CEO): Good morning, Matt.
Speaker
If we could start with you reiterated the guidance and that implies a fairly wide range of growth for the fourth quarter. Can you talk about some of the puts and takes we should keep in mind for the fourth quarter? You'll have the benefit of the MSA legal fee expiration, but any other detail that we should keep in mind would be helpful. Sal Mancuso (CFO): Yes. Good morning, Matt. I think you touched on one of the issues. Definitely. It's the MSA benefit from the expiration of the legal fund. I'll remind you too that we have an extra shipping day in the fourth quarter as well. So we were pleased to provide you with the guidance and very comfortable with it.
Speaker
Thank you. And as my second question, I'd like to ask about the discount category share dynamics. Marlboro had an impressive performance in the premium category, but discount share reaccelerated on a sequential basis. You have a lot of deep consumer insights data. Are you seeing diverging trends between cross-category movement for the premium versus the discount consumer? Billy Gifford (CEO): I think there's a little bit of that happening, Matt. I would point to really it's the economic strain that the consumer is under. I think you've seen it, we've been highlighting it. You see it in some of the C-store traffic that the consumer is under economic strain. And so from that standpoint, if they're staying with the cigarette category, they feel that economic strain. I would also highlight from a cigarette perspective, not directly to your discount question is the impact of illicit and the number of consumers that are moving over.
Speaker
Thank you, Billy. I'll pass it on.
Operator
Thank you. We will take our next question from Bonnie Herzog with Goldman Sachs. Please go ahead.
Speaker
All right, thank you. Good morning. I actually wanted to circle back on the guidance because. And maybe ask a little differently. Despite the stronger than expected Q3, you did choose to maintain your guidance and not narrow the range despite really only two months left in the year. So could you maybe help us understand the reasoning behind this? And if in some way you have limited visibility and then also your guidance assumes Q4 EPS growth will decelerate sequentially despite another extra shipping day and then the MSA stuff. So, I guess I assume a key driver of this is due to the unwind of the overshipments in Q3. And so if you could talk about that, if I just do a quick calculation, it looks like the shipment timing in Q3 was a two-point benefit versus maybe a one-point benefit from the extra day. So any color there would be helpful and how we should think about that for Q4. Sal Mancuso (CFO): Sure, we're pleased to be able to reaffirm our guidance. And certainly in the dynamic market that the tobacco industry is under in the U.S. with the lack of enforcement and things taking place that we're seeing the consumer being swayed by the number of illicit products, both the nicotine pouch and e-vapor, that's impacting across all categories. I think when you think about tightening, we feel good about it. Bonnie, there are always puts and takes quarter-to-quarter. As far as your question around shipments and inventories, you remember we had an extra shipping day in the third quarter. We have an extra shipping day in the fourth quarter. From an overall inventory standpoint, nothing really to highlight. I think you've seen it, you have fluctuations, but over the long term it tends to balance out.
Speaker
Okay, fair. But if I may, Billy, I mean just based on what you report with your shipments versus the adjusted inventory for the quarter, I mean there was a little bit of a timing benefit in the quarter and so maybe that's going to. Yes. Billy Gifford (CEO): Well, from a comparison standpoint, you certainly have the extra shipping day that occurred in the third quarter. And I would remind you you're going to have the extra shipping day that occurs in the fourth.
Speaker
Okay, I can take it offline. I'm just trying to make sure. I understand. Just because you're adjusted volume ex-trade inventory, you know, it was down 11.5, which is like a three-point difference in reported shipments. So again suggest that there was some timing differences in the quarter that could unwind in Q4. Okay. Billy Gifford (CEO): To make it terrible year-over-year, you adjust that shipping day out.
Speaker
Right. But I mean, I can take it offline. I didn't think it would be one extra, not three points. I didn't think based on my math, unless you really overshipped in one extra day. Anyway, I do have another question, if I may, on your relative price gap. It certainly continues to widen and it's now at 47%, and you've implemented four list prices price increases this year. So I guess I'd love to hear at this point if there's any change in your strategy and sort of how concerned are you about this widening price gap between Marlboro and the lowest competitive cigarette brand in the market? And I'm thinking about in the context of everything you called out with the pressures on the consumer and some of the market share gains we've been seeing from deep discount manufacturers as there has been some down trading pressure. Any color there would be helpful. Thank you. Sal Mancuso (CFO): Sure. I appreciate the question, Bonnie. I think it's important to remember that the price gap we’re showing on the metrics is the national price gap. Remember, as we've implemented RGM, it's allowed us to really look at price gaps in a store. And then you can look at within the portfolio of Marlboro of different price points within Marlboro. And implementing that, we're able to, we believe, more effectively, more efficiently apply the resources to the marketplace. Our idea would be to get to a consumer by consumer basis. We're not quite there yet, but it allows us to, from a pricing standpoint, these past prices, take pricing and then implement what we need to in the marketplace. You know, I would remind you the strategy of the overall combustible category is to maximize profitability over the long term while making appropriate investments in Marlboro balanced with the growth areas. And so we feel like we are successfully doing that. You highlighted that Marlboro continues to grow in the premium segment, and we'll continue to monitor it as we move forward.
Operator
Thank you. So we will take our next question from Faham Baig with UBS. Please go ahead.
Speaker
Good morning everyone. If it's okay, I might take the liberty of three questions. The first one goes back to your patent infringement lawsuit that JUUL has against NJOY. I know you shared a bit on this. And then there is a final determination date set for 23 of December, after which I understand there is a 60-day period before an exclusion order could be granted and NJOYs products have to. You have to stop importing NJOYs products. Previously, you've highlighted a couple of things, right? You've highlighted substantial equivalence applications as well as negotiating with JUUL to come up with a resolution. So can you please give us a bit more information on those SE applications when you expect to receive approvals, whether you've been able to now work around the four patents at concern as well as where the negotiation trends are, then I'll come back with my next two. Billy Gifford (CEO): Sure. Yes, you nailed it. As far as timing, we would expect the final determination towards the end of December. You are correct, the President has or trade representative, which is officially the President, has up to 60 days. If that elapses, an exclusion order would go into effect or if the trade representative notifies the ITC of approval before the 60 days. We did file PMP exemptions for three out of the four patents, and they were really for simple changes to the exterior of our NJOY product that we believe avoid those patents. And so we filed those. We've been in conversations with the FDA. They have let us know that they'll be looking at those applications as we progress towards the end of the year. Our teams internally are working for being able to have an avoidance of the fourth patent that was mentioned in the ITC case. And so we're looking at the whole process as part of the contingency because you never know how litigation would turn out and we feel good about that. As far as the negotiations with JUUL and through the mediator, nothing really to report there.
Speaker
Great, thanks. And the second question goes back to your pretty impressive EBIT margin performance in the smokables division. 350 basis points, if I remembered correctly. If I do the math, your controllable costs seem to be down about high single digits, which is pretty impressive given that they were running up double digits in the first half. Again, that's dependent on my math. But could you help clarify and if the math is right, what's driven that, please? Sal Mancuso (CFO): Sure. Yes. You are right. Controllable costs for this quarter are down. But if you go back, if you rewind the clock to April, when we were talking in the first quarter, controllable costs were up and at the time I shared it, we expected timing to play a factor in that and that's what you're really seeing. So as expected, we think that you're seeing a more normalized pattern over the long term, but within a short window, like a quarter, timing of costs does impact the controllable cost.
Speaker
Okay, so it's not something we should expect to continue. Sal Mancuso (CFO): No, I would not look at a quarter in a short window like that and extrapolate it. I would look at it over a longer period of time.
Speaker
Okay, thanks. And one final question. I think one of your peers has recently launched a heated tobacco offering which you'll be very familiar with. Can you maybe remind us what your expectations are for the success of this category over, let's say, the next five years and how it could potentially impact the current cigarette trends? Please. Billy Gifford (CEO): Yes. If you recall all the way back to our Investor Day when we talked about the three, what we saw as the three growing categories, unless something draconian comes out of the FDA, we expected e-vapor to be the largest because it was already in place and entrenched. Next was going to be nicotine pouch and then heated tobacco. It's something that we'll monitor. You recall that we have a joint venture with JT for the Ploom device, which we are still excited about. We look to file a combined PMTA MRTP in the first half of 2025. And so from that standpoint, we feel like it's something to monitor, but as far as the size of the categories, we feel like e-vapor will be the largest.
Speaker
Thank you so much. Appreciate it. Billy Gifford (CEO): Thank you.
Operator
Thank you. We will move next to Callum Elliott with Bernstein. Please go ahead.
Speaker
Hi. Good morning, guys. Thank you for the questions. Firstly, just a quick follow-up maybe on the litigation with JUUL. So you mentioned the tweaked product that you've submitted the SE application for. You also mentioned how you've tweaked this product to get around three of the four patents in question in the ITC case. My question is, how confident are you, given that the revised product still sort of infringes on this one patent, that the revised product would not be subject to an import ban from ITC? Billy Gifford (CEO): Yes, certainly anything can happen in litigation. The remaining patent was one of them that the ITC granted review of. With our petition, our teams, internally, as any good team will do, is working feverishly to avoid that patent as well. And so they're making great progress there. I think when you look underneath this column, if you want to draw a positive out of it, I think it shows that JUUL is worried about the success that NJOY has had in the marketplace thus far. And so we'll continue to move forward, but we're certainly pleased that we were able to file those PMTA exemptions for, like I said earlier, simple changes to the exterior of the product.
Speaker
Just a quick follow-up on that, Billy. If you make a further change to the product to circumvent this last patent, would that restart the timeline on the SE process or not? Billy Gifford (CEO): Yes. So from a standpoint of the final one, it would be considered a different application. Again, we believe with these kind of simple, if you will, exterior changes that the SE exemption process was really a contingency and the utmost of caution to go to the FDA. It really doesn't change how the device functions, what goes in and what comes out of the device. And we provided that data to the FDA.
Speaker
Okay, perfect. And then my second question is actually on something else that you mentioned, which is your partnership with Japan Tobacco for the Ploom device. And obviously, JT have recently closed an acquisition in the U.S. Cigarette space and become a more meaningful competitor there. So is there any change to that partnership following that acquisition, is my question. Billy Gifford (CEO): Yes, from the JV. It's progressing along. Remember, we set that up to really run into perpetuity. The teams are working well together on the application process. We're excited to continue progress there, and we really see no impact to the JV we have for the Ploom device.
Speaker
Okay, perfect. That's clear. And my final question is on the proposed rule that you mentioned, requiring the vaping imports to have a PMTA tracking number, hoping that you can maybe walk us through your expected timeline to get to the end of this process. Billy Gifford (CEO): Yes. What we told the FDA is we didn't really think it needed to go through the proposed rule process, that it was part of their jurisdiction already. So we'll see how they respond to that and how they respond to other comments that they receive. And we encourage them to expand it to nicotine pouch as well because we're seeing the same manufacturers that were putting illicit vapor in the marketplace just expanded their portfolio and putting a list of pouches in the marketplace.
Speaker
But any sort of rough guidelines of when you think it could come into place. Billy Gifford (CEO): I would like to be able to predict timing with the FDA, but we've been unable to do that thus far.
Speaker
Okay, thanks, Billy. Billy Gifford (CEO): Thank you.
Operator
It appears that we have no further questions at this time. I would now like to turn the call back to Mac Livingston for any closing remarks. Mac Livingston (Head of Investor Relations): Thanks to everybody for joining us and have a great day.
Operator
Thank you. And this does conclude today’s program. You may disconnect at any time.